ArticleLeukemia2023
Aberrant activation of TRIP13-EZH2 signaling axis promotes stemness and therapy resistance in multiple myeloma.
Abstract readLetter
In one paragraph
Article in Leukemia, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
5.6field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 18 citations in OpenAlex.
- Triptonide enhances DNA damage by inhibiting TRIP13‑mediated DNA repair and synergizes with bortezomib to suppress multiple myeloma.International journal of oncology · 2026Article
- The role of epigenetic modifications in hematological cancers.Frontiers in oncology · 2026Review
- Decoding TRIP13's Role in Gastric Cancer: Implications for Prognosis and Immune Response.Biomedicines · 2025Article
- TRIP13-induced NUSAP1 upregulation promotes CcRCC progression through EMT and PI3K/AKT/mTOR pathway.Journal of translational medicine · 2025Article
- Discovery of novel antimyeloma agents targeting TRIP13 by molecular modeling and bioassay.RSC medicinal chemistry · 2025Article
- Exosome-transmitted HSPA9 facilitates bortezomib resistance by targeting TRIP13/USP1 signaling in multiple myeloma.Cell communication and signaling : CCS · 2025Article
- Role of TRIP13 in human cancer development.Molecular biology reports · 2024Review
- A Bruton tyrosine kinase inhibitor-resistance gene signature predicts prognosis and identifies TRIP13 as a potential therapeutic target in diffuse large B-cell lymphoma.Scientific reports · 2024Article
- TRIP13 regulates progression of gastric cancer through stabilising the expression of DDX21.Cell death & disease · 2024Article
- EZH2 inhibition induces senescence via ERK1/2 signaling pathway in multiple myeloma.Acta biochimica et biophysica Sinica · 2024Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 4 institutions in 2 countries.
Li Xu *Department of Hematology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, 200120, China.ORCID http://orcid.org/0009-0003-6836-3537
Yingcong Wang *Department of Hematology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, 200072, China.
Guanli WangDepartment of Hematology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, 200120, China.
Shushan GuoDepartment of Hematology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, 200120, China.
Dandan YuDepartment of Hematology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, 200072, China.
Qilin FengDepartment of Hematology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, 200120, China.
Ke HuDepartment of Hematology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, 200120, China.
Gege ChenDepartment of Hematology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, 200120, China.
Bo LiCAS Key Laboratory of Receptor Research; State Key Laboratory of Drug Research; Drug Discovery and Design Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.ORCID http://orcid.org/0000-0002-4279-4596
Zhijian XuCAS Key Laboratory of Receptor Research; State Key Laboratory of Drug Research; Drug Discovery and Design Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.ORCID http://orcid.org/0000-0002-3063-8473
Xinyan JiaDepartment of Hematology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, 200120, China.
Yumeng LuDepartment of Hematology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, 200072, China.
Hui ZhangDepartment of Hematology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, 200120, China.
Xuejie GaoDepartment of Hematology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, 200120, China.
Shuaikang ChangDepartment of Hematology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, 200120, China.
Huaping WangDepartment of Hematology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, 200072, China.
Xiaosong WuDepartment of Hematology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, 200072, China.
Dongliang SongDepartment of Hematology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, 200120, China.
Guang YangDepartment of Hematology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, 200120, China.
Huabin ZhuDepartment of Hematology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, 200072, China.
Jinfeng ZhouDepartment of Hematology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, 200120, China.
Fenghuang ZhanMyeloma Center, Winthrop P. Rockefeller Cancer Institute, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, USA.ORCID http://orcid.org/0000-0001-5417-2973
Weiliang ZhuCAS Key Laboratory of Receptor Research; State Key Laboratory of Drug Research; Drug Discovery and Design Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.ORCID http://orcid.org/0000-0001-6699-5299
Jumei ShiDepartment of Hematology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, 200120, China. shijumei@tongji.edu.cn.ORCID http://orcid.org/0000-0002-8553-4559
Shanghai East Hospital · CNTongji University · CNChinese Academy of Sciences · CNWinthrop Rockefeller Foundation · US
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Multiple MyelomaATPases Associated with Diverse Cellular ActivitiesCell Cycle ProteinsCell Line, TumorEnhancer of Zeste Homolog 2 ProteinHumansSignal TransductionATPases Associated with Diverse Cellular ActivitiesCell Cycle ProteinsEnhancer of Zeste Homolog 2 ProteinEZH2 protein, humanTRIP13 protein, human
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.